0731 GMT - Medacta should continue to book above-market growth rates but market expectations currently underestimate growth normalization and the investment required to sustain expansion, Deutsche Bank says in a research note. "While Medacta's competitive advantages remain intact, sustaining its historical growth rates will become increasingly challenging as the business scales," Deutsche Bank says. The bank's 2028 organic sales, adjusted Ebitda and EPS estimates lie 3%, 6% and 9% below consensus, respectively. Deutsche Bank initiates the Swiss orthopedics company's stock at hold, with a target of 121 francs. Shares trade 1.9% lower at 113.20 francs.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.